<DOC>
	<DOCNO>NCT01571362</DOCNO>
	<brief_summary>The primary objective study determine analgesic efficacy safety ALO-02 extended-release capsule , compare placebo , subject moderate severe chronic low back pain .</brief_summary>
	<brief_title>A Research Study Investigational Drug ALO-02 ( Oxycodone Hydrochloride Naltrexone Hydrochloride ) Patients With Moderate Severe Chronic Low Back Pain</brief_title>
	<detailed_description />
	<mesh_term>Back Pain</mesh_term>
	<mesh_term>Chronic Pain</mesh_term>
	<mesh_term>Low Back Pain</mesh_term>
	<mesh_term>Oxycodone</mesh_term>
	<mesh_term>Naltrexone</mesh_term>
	<criteria>Moderatetosevere chronic low back pain present least 3 month . Require continuous aroundtheclock opioid analgesic extended period time . Refrain take opioid nonopioid medication study . Active within past 2 year history lumbosacral radiculopathy chronic low back pain due underlie disorder spinal stenosis neurologic impairment , cancer , infection , postsurgical intervention . Documented diagnosis ongoing pain due chronic pain condition may interfere assessment chronic low back pain . Active ongoing history alcohol drug abuse .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>oxycodone</keyword>
	<keyword>naltrexone</keyword>
	<keyword>chronic pain</keyword>
	<keyword>low back pain</keyword>
</DOC>